Home / ASCO Direct Highlights / ASCO Direct Highlights - Hawaii / Continuing Education Credits - Hawaii

Continuing Education Credits - Hawaii

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This activity is supported in part by educational grants from Abbvie, Inc., Celgene Corporation, Pfizer, Inc., and TESARO, Inc.

Target Audience

Multidisciplinary clinical cancer care team members including—but not limited to—medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

Overview

ASCO DIRECT™ HIGHLIGHTS MEETINGS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting, into a one-day program. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty will place abstract findings into clinical context and discuss how the results may change the current standard of care.

Objectives

At the end of this educational activity, participants should be able to:

  • Review highlights of the advances in clinical and translational research presented at the 2019 ASCO Annual Meeting
  • Identify emerging trends and strategies designed to improve the quality of survivorship care
  • Evaluate tools and resources in specific areas of cancer management that can be used to achieve effective cancer care delivery and improve the patient experience

Agenda

6:30 – 7:30 AM  Registration and Networking Breakfast

7:30 – 7:40 AM  Introduction and Pre-Activity Assessment

7:40 – 8:10 AM  Breast Cancer VK Gadi, MD, PhD

8:10 – 8:40 AM  Healthcare Delivery and Survivorship Jennie R. Crews, MD, MMM, FACP

8:40 – 9:10 AM  Hepatobiliary/Pancreatic/Gastrointestinal Cancers Philip Agop Philip, MD, PhD, FRCP

9:40 – 10:05 AM  Networking Break

10:05 – 10:35 AM  Melanoma and Skin Cancers Steven J. O’Day, MD

10:35 – 11:05 AM  Gynecologic Cancers Bradley J. Monk, MD, FACS, FACOG

11:05 – 11:40 AM   Genitourinary Cancers Sumanta Kumar Pal, MD

11:40 AM – 12:25 PM  Networking Lunch

12:25 – 12:55 PM  Leukemia and Lymphoma Ryan Lynch, MD

12:55 – 1:25 PM  Multiple Myeloma Ann Mohrbacher, MD

1:25 – 1:55 PM  CAR T-cell Therapies Keri Maher, DO, MS

1:55 – 2:25 PM  Quality Management and Care Improvement Keith D. Eaton, MD, PhD 

2:25 – 2:45 PM  Networking Break

2:45 – 3:15 PM  Cancer Genomics and Molecular Diagnostics Jeffrey Gregg, MD

3:15 – 3:45 PM  Lung Cancer Heather Wakelee, MD       

3:45 – 4:00 PM  Program Evaluation/Q&A

Register

Faculty

  • Breast Cancer, VK Gadi, MD, PhD, University of Washington; Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance
  • Healthcare Delivery and Survivorship, Jennie R. Crews, MD, MMM, FACP, SCCA Community Sites; SCCA Affiliate Network
  • Hepatobiliary/Pancreatic/Gastrointestinal Cancers, Philip Agop Philip, MD, PhD, FRCP, Karmanos Cancer Institute, Wayne State University
  • Melanoma and Skin Cancers, Steven J. O’Day, MD, John Wayne Cancer Institute
  • Gynecologic Cancers, Bradley J. Monk, MD, FACS, FACOG, Division of Gynecologic Oncology Arizona Oncology (US Oncology Network), University of Arizona College of Medicine; Creighton University School of Medicine at St. Joseph's Hospital Phoenix; USA Medical Director US Oncology Research Network - Gynecologic Program
  • Genitourinary Cancers, Sumanta Kumar Pal, MD, City of Hope
  • Leukemia/Lymphoma, Ryan Lynch, MD, University of Washington; Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance
  • Multiple Myeloma, Ann Mohrbacher, MD, USC/Kenneth Norris Comprehensive Cancer Center
  • CAR T-cell Therapies, Keri Maher, DO,MS, University of Arizona Cancer Center, University of Arizona, Tucson
  • Quality Management and Care Improvement, Keith D. Eaton, MD, University of Washington; Seattle Cancer Care Alliance
  • Cancer Genomics and Molecular Diagnostics, Jeffrey Gregg, MD, University of California, Davis Medical Center; Foundation Medicine, Inc.
  • Lung Cancer, Heather Wakelee, MD, Stanford University, Stanford Cancer Institute

 

Continuing Education

Accreditation Statement

Jointly Accredited Provider Logo In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

IPCE Logo

This activity was planned by and for the healthcare team, and learners will receive 7.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Credit Designation for Pharmacists
This application-based activity is approved for 7.0 contact hours of continuing pharmacy education credit JA4008106-9999-19-026-L01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 7.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

 

Name of Faculty or Presenter/Planner

Reported Financial Relationship

VK Gadi, MD, PhD

VK Gadi, MD PhD reported a financial interest/relationship or affiliation in the form of Consultant: SEngine Precision Medicine;  Novartis Pharmaceuticals Corp; Puma Biotechnology;  Daiichi Sankyo; Seattle Genetics;  Roche. Research grant: Roche. Ownership interest: SEngine Precision Medicine.

Jennie R. Crews, MD, MMM, FACP

Jennie R. Crews, MD, MMM, FACP reported no financial interest/relationships.

Philip Agop Philip, MD, PhD, FRCP

Philip Agop Philip, MD, PhD, FRCP reported a financial interest/relationship or affiliation in the form of Advisor: AbbVie Inc.; Caris Diagnostics Inc.; Celgene Corporation; Eisai Inc.; Halozyme Inc.; Ipsen Biopharmaceutical Inc.; Lexicon Pharmaceuticals Inc.; Lilly USA; Merck & Co, Inc.;  Novartis Pharmaceuticals Corp; Rafael Pharmaceuticals Inc.; Taiho Oncology Inc; Biolinx; Forty Seven Inc. Consultant: AbbVie Inc.; Celgene Corporation; Lilly USA; Merck & Co, Inc.;  Rafael Pharmaceuticals Inc Contracted Research: AAA Pharmaceutical Inc.;  Astellas Pharma Global Development Inc.; Boston Biomedical Pharma Inc.; Bristol-Myers Squibb Co.; Celgene Corporation; Daiichi Sankyo Inc.; Eisai Inc.; Gilead Sciences Inc.; Halozyme Inc.; Incyte Corporation; Lilly USA; Merck & Co, Inc.; Novocure; QED Therapeutics; Taiho Oncology Inc.; Biolinx; Thyme; Bayer Pharmaceuticals Corp; Forty Seven Inc. Data and Safety Monitoring Board: ASLAN Pharmaceuticals; Blueprint Medicines; Erytech Pharma SA; Lexicon Pharmaceuticals Inc. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co.; Celgene Corporation;  Ipsen Biopharmaceutical Inc.; Merck & Co, Inc.

Steven J. O’Day, MD

Steven J. O'Day reported a financial interest/relationship or affiliation in the form of Consultant: Array BioPharma; Biothera Pharmaceuticals, Inc.; Bristol-Myers Squibb Co.; Merck & Co, Inc.; Radimmune Therapeutics; ImaginAb. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co. Contracted research: Amgen; Biothera Pharmaceuticals, Inc.;  Exicure; Genocea Biosciences Inc.; Incyte Corporation; Oncotherapeutics; Ultimovacs; Viralytics.

Bradley J. Monk, MD, FACS, FACOG

Bradley Monk, MD, FACS, FACOG, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie, Inc.; Advaxis, Inc., Agenus; Amgen;  AstraZeneca Pharmaceuticals LP; ChemoCare; ChemoID; Clovis Oncology; Conjupro Bio-Pharmaceuticals; Easai, Inc.; Geistlich Pharma; Genmab; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc. - a pharmaceutical company of Johnson & Johnson; Mateon (Oxigene, Inc.); Merck & Co., Inc., Myriad Genetics, Inc.; NuCana; OncoMed Pharmaceuticals; OncoQuest, Inc.; OncoSec Medical Incorporated; Perthera, Inc.; Pfizer, Inc.; Precision Oncology; Puma Biotechnology; Genentech/Roche; Samumed; Takeda Oncology; Tesaro; VBL Therapeutics.  Serve(d) as a speaker or a member of a speakers bureau for:  AstraZeneca Pharmaceuticals LP; Clovis Oncology; Janssen Pharmaceuticals, Inc. - a pharmaceutical company of Johnson & Johnson; Genentech/Roche; Tesaro.

Sumanta Kumar Pal, MD

Pending

Ryan Lynch, MD

Ryan Lynch, MD reported a financial interest/relationship or affiliation in the form of Research grant: Takeda Oncology; Juno Therapeutics; Rhizen Pharmaceuticals SA; Incyte Corporation; TG Therapeutics, Inc. 

Ann Mohrbacher, MD

Ann Mohrbacher, MD reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for Takeda Oncology; Genentech.

Keri Maher, DO, MS

Keri Maher, DO, MS reported a financial interest/relationship or affiliation in the form of Advisor: Agios Pharmaceuticals.

Keith D. Eaton, MD, PhD 

Keith D. Eaton, MD, PhD reported a financial interest/relationship or affiliation in the form of Research grant: Mirati Pharma

Jeffrey Gregg, MD

Jeffrey Gregg, MD reported a financial interest/relationship or affiliation in the form of Consultant: Foundation Medicine, Inc. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corp.
Research grant: AstraZeneca Pharmaceuticals LP.

Heather Wakelee, MD

Heather Wakelee, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Xcovery; Janssen Biotech, Inc.; Mirati Therapeutics, Inc.; Merck & Co.; Takeda; Genentech/Roche. Contracted research: ACEA Biosciences; Arys Therapeutics; AstraZeneca Pharmaceuticals LP/Medimmune; Bayer HeatlhCare, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; Exelixis, Inc.; Gilead; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Pharmacyclics Inc.; Xcovery.


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Planner/Manager/Reviewer

Reported Financial Relationship

Keola Beale, MD

Nothing to disclose

Chuck Miller, MD

Nothing to disclose

Emily Touloukian, DO

Nothing to disclose

Asutosh “Bobby” Gor, MD

Nothing to disclose

Jennie Crews, MD, MMM, FACP

Nothing to disclose

Ali McBride, PharmD, MS, BCOP

Advisor: Bristol-Myers Squibb

John Allan, MD

Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

Stuart P. Feldman, MD

Nothing to disclose

Gene Saylors, MD

Nothing to disclose

Leigh Boehmer, PharmD, BCOP

Nothing to disclose

Mary Stanley

Nothing to disclose

Robert Mocharnuk, MD

Common stock: Merck

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Dee Morgillo, MEd.,CHCP

Nothing to disclose


Disclaimer  

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit  

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be emailed to you within 3 weeks. For pharmacists, your record will be uploaded to CPE Monitor.

Co-Hosts

HSCO-logo-250x266    logo-ACCC-200x80